GPC2

GPC2 (cerebroglycan) is a GPI-anchored heparan sulfate proteoglycan that functions in nervous system development and is re-deployed as an oncofetal cell-surface antigen in pediatric cancers (PMID:8294498, PMID:28898695). During neural development it is expressed transiently in immature neurons around final mitosis and is polarized to axons and growth cones during active axon outgrowth, consistent with a role in axon growth or guidance (PMID:8294498, PMID:9133438). In neuroblastoma, GPC2 surface expression is driven by MYCN transcriptional activation and somatic gain of the locus, and the protein is required for tumor cell proliferation (PMID:28898695); an analogous tumor-specific program operates in retinoblastoma through the E2F1 transcription factor (PMID:38864848). In prostate cancer, GPC2 acts upstream of MDK to activate PI3K/AKT signaling and drive proliferation, migration, and invasion (PMID:39014225). Its restricted, tumor-associated surface display makes it a tractable immunotherapy target: a D3 antibody recognizes a conformational extracellular epitope resolved by crystallography, and the corresponding pyrrolobenzodiazepine ADC kills tumor cells via DNA damage and apoptosis (PMID:34337560) while triggering immunogenic cell death that reprograms the tumor microenvironment toward macrophage and T cell infiltration (PMID:36460335). GPC2-directed CAR T cell efficacy is constrained by CXCL1/2-recruited myeloid-derived suppressor cells, a barrier that can be overcome by CXCR2 engineering (PMID:40437756).

1. 1994 High

   Established GPC2 as a distinct molecular entity by cloning it as a GPI-anchored heparan sulfate proteoglycan of the glypican family with developmentally restricted neural expression.

   Evidence Molecular cloning, sequence analysis, and in situ hybridization

   PMID:8294498

   Open questions at the time

   • Functional consequence of GPI anchorage and HS attachment not tested
   • No binding partners or signaling role identified
2. 1997 Medium

   Resolved the subcellular distribution of the protein, showing axon/growth-cone polarization that ties GPC2 to active axon growth rather than mature neuronal function.

   Evidence Monospecific antibody immunohistochemistry in hippocampal neurons at defined developmental stages

   PMID:9133438

   Open questions at the time

   • Causal role in axon guidance not demonstrated by loss-of-function
   • Molecular mediators of polarized targeting unknown
3. 2017 Medium

   Connected GPC2 oncofetal re-expression to an oncogenic driver and to tumor cell fitness, defining it as a candidate neuroblastoma target.

   Evidence RNA-seq, copy-number analysis, MYCN transcriptional assays, and knockdown with proliferation readout

   PMID:28898695

   Open questions at the time

   • Downstream proliferative mechanism in neuroblastoma not defined
   • Direct MYCN binding at the locus not fully resolved
4. 2021 High

   Defined the molecular basis of tumor-selective targeting by mapping a conformational D3 epitope and validating an ADC kill mechanism.

   Evidence 3.3 Å crystal structure of D3-GPC2-Fab/GPC2 plus cytotoxicity assays with DNA damage/apoptosis readouts

   PMID:34337560

   Open questions at the time

   • Structural basis of GPC2's native ligand interactions still unknown
   • Determinants of tumor- vs normal-tissue epitope specificity not fully characterized
5. 2022 High

   Extended ADC mechanism from direct cytotoxicity to immune engagement, showing GPC2 ADC triggers immunogenic cell death and remodels the tumor immune microenvironment.

   Evidence ICD biomarker assays, syngeneic vaccination/rechallenge, immune profiling (RNA-seq, CyTOF, flow), and in vivo immune depletion

   PMID:36460335

   Open questions at the time

   • Antigen-specific adaptive immunity to GPC2 not directly proven
   • Durability of immune reprogramming across tumor types untested
6. 2024 Medium

   Showed that tumor-specific GPC2 transcriptional control is context-dependent, with E2F1 driving expression in retinoblastoma distinct from MYCN in neuroblastoma.

   Evidence Expression analysis in retinoblastoma patient samples and cellular models with E2F1 assessment

   PMID:38864848

   Open questions at the time

   • Direct E2F1 occupancy at the GPC2 promoter not shown
   • Functional requirement for GPC2 in retinoblastoma not tested
7. 2024 Medium

   Placed GPC2 in a defined signaling pathway by demonstrating it acts upstream of MDK to activate PI3K/AKT and drive malignant phenotypes in prostate cancer.

   Evidence Knockdown/overexpression with MDK rescue and PI3K/AKT pathway and proliferation/migration/invasion assays

   PMID:39014225

   Open questions at the time

   • Physical GPC2-MDK interaction not directly demonstrated
   • Whether the MDK/PI3K-AKT axis operates in neuroblastoma unknown
8. 2025 Medium

   Identified an immune-suppressive barrier to GPC2 cell therapy and an engineering solution, showing CXCL1/2-recruited MDSCs inhibit CAR T cells and CXCR2 arming restores efficacy.

   Evidence Syngeneic immune profiling, ex vivo MDSC inhibition, and CXCR2-armored CAR T migration/cytotoxicity assays in vitro and in vivo

   PMID:40437756

   Open questions at the time

   • Generalizability of MDSC suppression across patient tumors unknown
   • Long-term persistence and safety of CXCR2-armored CAR T not established

• The native ligand-binding and signaling function of GPC2 in normal axon development, and whether this overlaps with its tumor-promoting MDK/PI3K-AKT activity, remains unresolved.
• No direct molecular function assigned to the heparan sulfate chains
• Mechanistic link between developmental axon role and oncogenic signaling unexplored